0001127537-26-000025
SEC filingQ1 revenue declined 8.7% to $20.6M amid topline pressures, offset by gross margin expansion to 77.9% from favorable geographic mix and operating loss improvement of 11.0% to -$13.0M, reflecting cost discipline.
Revenue of $20.6 million in Q1 FY2026 declined 8.7% from $22.5 million in the prior year quarter. This reflects fluctuations in sales of Pulmonx products, which are driven by volume of cases or procedures performed, the average number of Zephyr Valves used per patient, pricing, discounts, incentives, and mix of U.S. and international sales. Investors should note that such factors contribute to period-to-period variability, with ongoing impacts from geographic mix, customer discounts, support services, and potential seasonality.
Gross profit was $16.0 million, slightly down 1.8% from $16.3 million, yet gross margin expanded to 77.9%. Management attributes this increase primarily to geographic mix during the three months ended March 31, 2026. The company has capacity to significantly increase manufacturing production under its current operating model and infrastructure. Over the long term, gross margin may improve further as production volume increases, spreading fixed manufacturing costs over a larger number of units and reducing per-unit manufacturing costs. If revenue grows and more units are sold, this dynamic would reduce manufacturing costs on a per-unit basis and enhance gross margin. However, failure to efficiently increase production capacity could hinder timely order fulfillment, limit sales growth, and cause operating margins to fluctuate or decline.
Operating loss improved to -$13.0 million, a 11.0% reduction from -$14.6 million year-over-year, with operating margin at -62.9%. This narrowing reflects effective cost discipline despite revenue headwinds. Net loss was -$13.7 million, 5.5% better than -$14.4 million prior year, delivering diluted EPS of -$0.33 compared to -$0.36.
Clinical trial expenses, including those for the AeriSeal System development program, encompass trial design, site development, study costs, data management, travel, and product costs for clinical activities. The company believes it can meet longer-term cash requirements through available cash, product sales, debt financings, and potential equity offerings.